• Myeloma UK
  • Clinical Service Excellence Programme
Myeloma Academy
Sign inRegister
Menu
  • Home
  • CPD & Learning
    • Myeloma Nurse Learning Programme
    • My CPD Portfolio
    • Challenging Cases
    • Close
  • Library
    • Guidelines
      • Complications
      • COVID-19 guidance
      • General haemato/oncology
      • Imaging & Analysis
      • Management & Treatment
      • Palliative Care
      • Presentation & Diagnosis
      • Related conditions
      • Close
    • Patient Support and Information
    • Medical animations
    • Remote consultation video
    • Close
  • Resources
    • Myeloma Drug Finder
    • Myeloma Trial Finder
    • Assessment tools
    • Myeloma Spotlight
    • Primary care education
    • Secondary care education
    • Myeloma health economic model
    • Laboratory Practice
    • Close
  • News & Events
    • News
    • Event calendar
    • Meeting highlights
    • Close
  • CSEP
  • About Us
    • Contact Us
    • Close
Menu back  
 

Current treatments

The Feasibility and Efficacy of Dose-Adjusted Bortezomib, Melphalan and Dexamethasone for Transplantation-Ineligible Patients with Newly Diagnosed Multiple Myeloma.
Obama K. Acta Haematol. 2015 Jun 11;134(4):229-230. [Epub ahead of print]/

Biosimilar filgrastim (Zarzio®) vs Lenograstim (Myelostim®) for peripheral blood stem cell mobilization in adult patients with myeloma and lymphoma: A single center experience.
Marchesi F et al. Leuk Lymphoma. 2015 Jun 23:1-12. [Epub ahead of print].

Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials.
Liu X et al. Onco Targets Ther. 2015 Jun 15;8:1459-69. doi: 10.2147/OTT.S84828. eCollection 2015.

High-dose melphalan plus thiotepa as conditioning regimen before second autologous stem cell transplantation for “de-novo” multiple myeloma patients: a phase II study.
Musso M et al. Biol Blood Marrow Transplant. 2015 Jun 19. pii: S1083-8791(15)00413-9. doi: 10.1016/j.bbmt.2015.06.011. [Epub ahead of print].

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
Niesvizky R et al. J Clin Oncol. 2015 Jun 8. pii: JCO.2014.58.7618. [Epub ahead of print].

  • Guidelines
  • Patient Support and Information
  • Medical animations
  • Remote consultation video
Bottom menu

Charity No. SC 026116
Myeloma UK
22 Logie Mill
Beaverbank Business Park
Edinburgh
EH7 4HG